FMTX News and Press, Forma Therapeutics Holdings Inc. From 09/01/22

Novo Nordisk and Forma Therapeutics, Holdings Inc. (Nasdaq: FMTX) today announced that they have entered into a definitive agreement under which Novo Nordisk will acquire Forma Therapeutics for $20 per share in cash, which represents a total equity value of $1.1 billion. Forma Therapeut...

Summary 72% technical buy signal. 15 new highs and up 59.18% in the last month. Price targets from $23 to $53. The Chart of the Day belongs to the biotechnology company Forma Therapeutics ( FMTX ). I found the stock by sorting the Russell 3000 Index stocks fi...

The shares of clinical-stage biotech Rigel Pharmaceuticals, Inc. ( NASDAQ: RIGL ) continued the recent momentum to add more than 7% at the market open on Thursday, reaching the highest level since June. Ahead of the uptick in RIGL shares, H.C. Wainwright more than doub...

Over the past few days, there have been some monster moves across a number of Russell 3,000 stocks. Taking a look at the Russell 3,000 members that had at least been cut in half from the time of the index’s high on January 3rd through the low on June 16th, followed by a rally o...

Forma Therapeutics Holdings Inc. (FMTX) Q2 2022 Earnings Conference Call August 5, 2022 8:00 AM ET Company Participants Adam Bero - Investor Relations Frank Lee - President and Chief Executive Officer Agustin Melian - Executive Vice President, Research and Develo...

Forma Therapeutics press release ( NASDAQ: FMTX ): Q2 GAAP EPS of -$1.10 misses by $0.11 . Cash, cash equivalents and marketable securities were $395.9 million as of June 30 2022. For further details see: Forma Therapeutics GAAP EPS of -$1.10 misses by $0.11 ...

Announced analyses from Phase I study of etavopivat in sickle cell disease indicated reduction of reported pain-related adverse events, supporting potential to reduce vaso-occlusive crises Recently entered into an exclusive license agreement with Rigel Pharmaceuticals, Inc. fo...

Rigel Pharmaceuticals and Forma Therapeutics Announce Licensing Agreement for Olutasidenib, a Novel Mutant IDH1 Inhibitor for the Potential Treatment of Relapsed or Refractory Acute Myeloid Leukemia PR Newswire Registrational Phase 2 data demonstrate olutasidenib's pot...

Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on sickle cell disease (SCD), prostate cancer and other rare hematologic diseases and cancers, today announced that it will release second quarter 2022 financial results Friday, Augu...

Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on sickle cell disease, prostate cancer and other rare hematologic diseases and cancers, today announced that its Board of Directors granted to Agustín Melián, M.D. and Linea A...